Dr. Norman Sharpless was named as interim head of FDA starting May 1, 2019. Dr. Sharpless is a cancer doctor with a strong background in research and medical science. Sharpless’ appointment is not seen as political, and the Trump administration has not indicated whether it plans to nominate a different person for the permanent commissioner position. Sharpless’ official position on cannabis and CBD is unstated, though as former director of the National Cancer Institute, he is certainly aware of the use of cannabis and CBD in the treatment of cancer symptoms, and the NCI website states that “cannabis has been used for medicinal purposes for thousands of years…[However] the U.S. Food and Drug Administration has not approved Cannabis as a treatment for cancer or any other medical condition.” NCI Cannabis and Cannabinoids (PDQ®) (2019). Given the approval of Epidiolex in June 2018, the NCI position statement might stand some updating, and Dr. Sharpless may be instrumental in advancing FDA policy on cannabis and CBD for non-medical purposes as well.